Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: An historic review

Clinical Cases in Mineral and Bone Metabolism

Volumn 6, Issue 3, 2009, Pages 210-219

  Bolasco, Piergiorgio ^a  

^a Territorial Department of Nephrology and Dialysis   (Italy)

Author keywords

Chronic kidney disease stages 3 4; Chronic renal failure stages 3 4; Secondary hyperparathyroidism; SHPT

Indexed keywords

24,25 DIHYDROXYCOLECALCIFEROL; ALFACALCIDOL; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM DERIVATIVE; CALCIUM KETOVALIN; CHELATING AGENT; CIMETIDINE; CITRATE CALCIUM; DOXERCALCIFEROL; PARACALCITOL; PARATHYROID HORMONE; PHOSPHORUS DERIVATIVE; PROPRANOLOL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

BLOOD VESSEL CALCIFICATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DIETARY INTAKE; DISEASE SEVERITY; DRUG SAFETY; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; MORBIDITY; NUTRITIONAL STATUS; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SHORT SURVEY; UREMIA;

EID: 76749128619     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (112)

1. NKF K/DOQI. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification Guideline and 4.1. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD. 2002
2. Eknoyan G, Levin A, Levin NW. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;43(suppl 3):S1-S201.
3. Kramer H, Toto R, Peshock R et al. Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol. 2005;16:507-513.
4. Reichel H, Drueke T, Ritz E. Skeletal disorders. In: Davison AM, Cameron JS, Grunfeld JP, Kerr DNS, Ritz E, Winearls C, eds.Oxford Textbook of Clinical Nephrology. 2nd edition, Oxford: Oxford University Press. 1997:1954-1981.
5. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89(12):1147-1154.
6. Mehrothra R. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. J Ren Nutrition. 2006 Apr;16(2):100-118.
7. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001 Jan;37(1 Suppl 2):S54-7.
8. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial. 2007 Jul-Aug;20(4):302-8. Review.
9. Llach F, Yudd M. The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant. 1998;13 (Suppl 3):57-61.
10. Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb;14(1):18-27.
11. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006 Jan;69(1):33-43.
12. Marco MP, Martínez I, Amoedo ML, Borràs M, Saracho R, Almirall J, Fibla J, Fernández E. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients. Kidney Int. 1999 Oct;56(4):1349-53.
13. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid mediated osseous abnormalities in uremia. J Clin Endocrinol Metab. 1992;75:145-150.
14. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant. 1996;11:813-819.
15. Barsotti G, Cupisti A. The role of dietary phosphorus restriction in the conservative management of chronic renal disease. J Ren Nutr 2005 Jan;15(1):189-92.
16. Schaefer K, Von Herrath D, Asmus G, Umlauf E. The beneficial effect of ketoacids on serum phosphate and pharathyroid hormone in patients with chonic uremia. Clin Nephrol. 1998 Aug; 30(2):93-96.
17. Barsotti G, Cupisti A, Morelli E, Meola M, Cozza V, Barsotti M, Giovannetti S. Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation. Nephron. 1998;79(2):137-141.
18. Areste N, Amor J, Cambil T, Salgueira M, Sanchez-Palencia R, Paez C, Gomez O, Palma A. Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate. Nefrologia. 2003;23(Suppl 2):64-68.
19. Lafage-Proust M-H, Combe C, Barthe N, Aparicio M. Bone Mass and Dynamic Parathyroid Function According to Bone Histology in Nondialyzed Uremic Patients after Long-Term Protein and Phosphorus Restriction The Journal of Clinical Endocrinology & Metabolism. 1999;84(2):512-519.
20. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
21. NKF K/DOQI. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Guideline and 4.1. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD. Am J of Kidney Disease. 2002;39:2 supplement february 2002.
22. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520-528.
23. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. Am J Kidney Dis. 2005 Nov;46(5):925-32.
24. NKF K/DOQI. Therapy in Patients With Stages 3 and 4 CKD. Evaluation of serum phosphorus levels. Guideline 3.1. 2002
25. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW. PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007 Oct;22(10):2909-2916.
26. Savica V, Calò AL, Monardo P, Santoro D, Bellinghieri G. Phosphate binders and management of hyperphosphatemia in endstage renal disease. Nephrol Dial Transpl. 2006;21:2065-2068.
27. Tsukamoto Y, Mohya R, Nagaba Y, Morishita T, Izumida I, Okubo M. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. Am J Kidney Dis. 1995 Jun; 25(6):879-886.
28. Clark AGB, Oner A, Ward G, Turner C, Rigden SPA, Haycock GB, Chantler C. Safety and Efficacy of Calcium Carbonate in Children with Chronic Renal Failure. Nephrol Dial Transplant. 1989;4:539-544.
29. Moriniere P, Roussel A, Tahiri Y, de Fremont JF, Maurel G, Jaudon MC, Gueris J, Fournier A. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc. 1983;19:784-7.
30. NKF K/DOQI. Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 5.5 Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD. 2002.
31. Locatelli F, Cannata-Andía JB, Drüeke TB, Hörl WH, Fouque D, Heimburger O and Ritz E. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hypeiphosphataemia. Nephrol Dial Transplant. 2002;17: 723-731.
32. Saha H, Pietilä K, Mustonen J, Pasternack A, Mörsky P, Seppälä E, Reinikainen P. Acute effects of calcium carbonate and citrate on secondary hyperparathyroidism in chronic renal failure. Am J Nephrol. 1991;11(6):465-469.
33. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. 1990;38:937-941.
34. Duggal A, Martin H, Zhorov E, Dagher R, Plone MA, Goldberg J and Burke SH. Novel dosage forms and regimens for Sevelamer-based phosphate binders. J Ren Nutr. 2006 Jul;16(3):248-52.
35. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
36. Russo D, Corrao S, Miranda I et al. Progression of coronary artery calcification in pre-dialysis patients. Am J Nephrol. 2007;27:152-158.
37. Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004 Sep;66(3):1239-47.
38. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B; Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007 Oct;22(10):2856-66.
39. Suñer M, Guerrero A, Montes R, Rivera M, Ruiz A, Martínez-García M, Pérez-Valdivia MA y Mateos J. Tratamiento de la hiperfosfatemia con sevelamer en pacientes con insuficiencia renal crónica avanzada. Nefrologia. 2004;24:2.
40. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A and Andreucci VE. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International advance online publication, 2007; doi:10.1038/sj.ki.5002518.
41. Freemont AJ, Hoyland JA, Denton J. The effects of lhantanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol. Dec 2005;54(6):428-437.
42. Ben-Dov IZ, Pappo O, Sklair-Levy M, Galitzer H, Ilan Y, Naveh-Many T, Silver J. Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant. Feb 2007;22(2):362-8.
43. Behets GJ, Dams G, Vercauteren SR et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol. 2004;15:2219-2228.
44. Lacour B, Lucas A, Auchere D et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28 day oral administration. Kidney Int. 2005;67:1062-1069.
45. Webster I, Gill M. Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients. EDTA, Lisbon, Portugal,; Abstract SP268 2004.
46. Alfrey A. Aluminum intoxication. ? Engl J Med. 1984;310:1113-1115.
47. Mak RH, Turner C, Thompson T, Powell H, Hayocock GB, Chantler C. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose of phosphate binders: calcium carbonate versus aluminum hydroxide. Br Med J (Clin Res Ed). Sep 7 1985;291(6496):623-627.
48. Schaefer K, von Herrath D, Erley CM. Treatment of uremic hyperphosphatemi: is there still a need for aluminum salts? Am J Nephrol. 1988;8(3):173-8.
49. Hergesell O, Ritz E. Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant. 2002;17:14-17.
50. Berl T, Berns AS, Hufer WE et al. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med. 1978;88:774-780.
51. Memmos DE, Eastwood JB, Talner LB et al. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patiente receiving maintenance haemodialysis. Br Med J (Clin Res Ed). 1981;282:1919-1924.
52. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994;45:1710-1721.
53. Norman PE, Powell JT. Vitamin D shedding light on the development of disease in peripheral arteries. Arteriosler Thromb Vasc Biol. 2005;25:39-46.
54. Andress D. Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33-43.
55. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitaminD3. Semin Dial. Jul-Aug 2007;20(4):316-24.
56. Marco MP, Martínez I, Amoedo ML, Borràs M, Saracho R, Almirall J, Fibla J, Fernández E. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients. Kidney Int. Oct 1999;56(4):1349-53.
57. Healy MD, Malluche HH, Goldstein DA et al. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med. 1980;140:1030-1033.
58. Baker LR, Abrams L, Roe CJ et al. 1,25(OH)2D3 administration inmoderate renal failure: a prospective double-blind trial. Kidney Int. 1989;35:661-669.
59. Coburn JW, Maung HM, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43:877-890.
60. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM. Meta-analysis: vitamin D compounds in chronic kidney disease. Annal Int Med. 2007 Dec;147(12):840-861.
61. Ritz E. Küster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, Heidland A. Low-dose calcitriol prevents the rise in 1.84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant. 1995 Dec;10(12):2228-34.
62. Christiansen C, Rødbro P, Christensen MS, Hartnack B, Transbøl I. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet. 1978 Sep 30;2(8092 Pt 1):700-703.
63. Stavroulopoulos A, Porter CJ, Roe SD, Hosking DJ, Cassidy MJ. Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton). 2008 Feb;13(1):63-67.
64. Eastwood JB, de Wardener HE, Gray RW, Lemann JL, Jr. Normal plasma 1,25(OH)D2 vitamin D concentrations in nutritional osteomalacia. Lancet. 1979;314:1377-1378.
65. Couttenye MM, D'Haese PC, Verschoren WJ, Behets GJ, Schrooten I, De Broe ME. Low bone turnover in patients with renal failure. Kidney Int Suppl. 1999 Dec;73:S70-6.
66. Witmer G, Margolis A, Fontaine O, Fritsch J, Lenoir G, Broyer M, Balsan S. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int. 1976 nov; 10 (5): 395-408.
67. Teitelbaum SL, Bone JM, Stein PM, Gilden JJ, Bates M, Boisseau VC, Avioli LV. Calcifedol in chronic renal insufficiency. Skeletal response. JAMA. 1976 Ian; 235 (2): 164-167.
68. Woitge HW, Knothe A, Witte K, Schmidt-Gayk H, Ziegler R, Lemmer B, Seibel MJ. Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res. 2000 Dec;15(12):2443-50.
69. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res. 2004 Aug;19(8):1221-30.
70. Adams JS, Clemens TL, Parrish JA, Holick MF. Vitamin D synthesis and metabolism after ultraviolet irradiation of normal and vitamin D deficient subjects. N Engl J Med. 1982;306:722-725.
71. Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail. 2008;30(4):407-10.
72. Massry SG, Goldstein DA, Malluche HH. Current status of the use of 1.25(OH)2D3 in the management of renal osteodystrophy. Kidney Int. 1980 Oct;18(4):409-18. Review.
73. Brancaccio D, Bommer J, Coyne D. Vitamin D receptor Activator selectivity in the treatment of secondary hyperparathyroidism; understanding the difference among therapies. Drugs. 2007;67(14):1981-1998.
74. Nordal KP, Dahl E, Halse J, Attramadal A and Flatmark A. Longterm low-dose calcitriol treatment in preanalysis chronic renalfailure: can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant. 1995;10:203-206.
75. Tougaard L, Sorensen E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AW. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet. 1976 May 15;1(7968):1044-7.
76. Coen G, Mazzaferro S, Bonucci E, Ballanti F, Massimetti C, Donate G, Landi A, Smacchi A, Delia Rocca C, Cinotti GA. Treatment of secondary hyperparathyroidism of prediaysis chronic renal faillure with low doses of 1,25(OH)2D3: humoral an histomorphometric results. Min Electrolyte Metab. 1986;12(5-6):375-382.
77. Singh NP, Sahni V, Garg D, Nair M. Effect of pharmacological suppression of secondary hyperparathyroidism on cardiovascular hemodynamics in predialysis CKD patients: a preliminary observation. Hemodial Int. 2007 Oct;11(4):417-423.
78. Panichi V, Andreini B, De Pietro S, Migliori M, Taccola D, Giovannini L et al. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialitic renal failure. Clin Nephrol. 1998;49:245-250.
79. Birkenhäger-Frenkel DH, Pois H, Zeelenberg J, Eijgelsheim JJ, Kortz RA, Hüpscher EA, Van Geelen J, Van Berkum FN, Birgenhäger JC. Effects of 1 alpha-hydroxyvitaminD3 on various stages of predialysis renal bone disease. Bone Miner. 1989 Jul; 6 (3): 311-322.
80. Rix M, Eskilden P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004;19:870-876.
81. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358-363.
82. Bordier P, Zingraff J, Gueris J, Jungers P, Marie P, Pechet M, Rasmussen H. The effect of 1alpha(OH)D3 and 1alpha(OH)2D3 on the bone in patients with renal osteodystrophy. The Am J Med. 1978 Jan; 64(1):101-107.
83. Pietrek J, Kokot F, Kuska J. Effect of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency. Int Urol Nephrol. 1978;10(2):153-160.
84. Ala-Houhala M, Holmberg C, Ronnholm K, Paganus A, Laine J, Koskimies O. Alphacalcidol oral pulses normalize uremic hyperparathyroidism prior to dialysis. Pediatr Nephrol. Dec 1995; 9 (6): 737-741.
85. Coburn JW, Maung HM, Elangovan L et al. Doxecalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. May 2004;43(5):877-890.
86. ClinicalTrials.gov registration number: NCT00285467 (clinical trials). Comparison of cholecalciferol versus doxecalciferol in the treatment of secondary hyperparathyroidism in chronic kidney disease stage three and four. Accessed at http//clinicaltrials.gov/ct/show/NCT00285467 on 10 October 2007.
87. Zisman AL, Hristova M, Tammy Ho L, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27:36-43.
88. Cheng S, Coyne D. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease. Expert Opin Pharmacother. Apr 2006;7(5):617-2.
89. Abboud H, Coyne D, Smolenski O, Anger M, Lunde N, Qiu P, Hippensteel R, Pradhan RS, Palaparthy RV, Kavanaugh A, Melnick JZ, Williams LA, Battle D). A comparison ot dosing regimens of paricalcitol capsule for the treatment ot secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol. 2006;26(1):105-14. Epub 2006 Mar 14.
90. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19:1174-1181.
91. Coyne D. Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. Am J Kidney Dis. 2006;47(2): (February), 263-276.
92. Brown AJ, Finch J, Griett M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol on the intestine. Endocrinology. 1995;133:1158-1164.
93. Brown AJ, Finch J, Griett M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E). The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol on the intestine. Endocrinology. 1995;133:1158-1164.
94. Moe SM, Chertow GM, Coburn JW et al. Achieving NKFK/DOQI bone metabolism and disease treatment goals with cinacalcet HCI. Kidney Int. 2005;67:760-771.
95. Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM. Management of Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Endocrine Practice. 2008 January / Februarys;14(1):18-27.
96. Cunningham J, Urena P, Reichel H et al. Long-term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end-stage renal diesease (ESRD). XLII Congress of the ERA-EDTA, Abstract 2005.
97. Cunningham J, Danese M, Olson K, Klassen P, Chertow G. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture and health-related quality of lite in secondary hyperparathyroidism. Kidney Int. Oct 2005;68(4):1793-800.
98. Sensipar® (cinacalcet HCI). Full prescribing information. Thousand Oaks (CA); Amgen Inc. 2004
99. Charytan C, Coburn JW, Chonchol M, Herman J, Lien HY, Liu WL, Klassen PS,McCary LC and Pichette V. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. July 2005;46(1):58-67.
100. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCI in Participants With CKD Not Receiving Dialysis. Am J Kidney Dis. 2008 Dec 23.
101. Schlieper G, Floege J.Calcimimetics in CKD-results from recent clinical studies. Pediatr Nephrol. Jul 2 2008.
102. Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clinical Therapeutics. 2005;27(11):1725-1751.
103. Peters BS, Moyses RM, Jorgetti V, Martini LA. Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol. 2007;39(4):1251-6. Epub 2007 Aug 7.
104. Copley JB, Hui SL, Leapman S, Siemenda CW, Johnston CC. Longitudinal study of bone mass in end-stage renal disease patients: etfects of parathyroidectomy for renal osteodystrophy. J Bone Miner Res. 1993 Apr;8(4):415-422.
105. Caro JF, Besarab J, Burke JF, Glennon JA. A possible role for propranolol in the treatment of renal osteodistrophy. Lancet. 1978 Aug;2(8087):451-454.
106. Besarab A, Caro JF, Ihle BU, Glennon JA, Fischer JA. Suppression of secondary hyperparathyroidism by propanolol in renal failure patients. Nephron. 1981;27(3):127-133.
107. Fiore CE, Lunetta M, Kanis JA. Long-term effects of histamine H2-receptor antagonists on serum parathyroid hormone in chronic renal failure. Clin Endocrinol (Oxf). Sep 1985;23(3):277-282.
108. Torres PU, Prié D, Beck L, Friedlander G. New Therapies for Uremic Secondary Hyperparathyroidism. Journal of Renal Nutrition. 2006;16(2):87-99.
109. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005 Nov;68(5):1973-81.
110. Cozzolino M, Brancaccio D. Is PTH a Risk Factor for Cardio-Vascular Calcifications in Haemodialysis? Nephrol Dial Transplant. Dec 9 2007.
111. Cozzolino M, Mazzaferro S, Pugliese F, Brancaccio D. Vascular calcification and uremia: what do we know? Am J Nephrol. 2008;28(2):339-46.
112. Torres PU. Cinacalcet HCI: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J of Renal Nutr. 2006;16(3):253-258.